查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601191

藥物安全檢測和藥物安全軟體市場：按產品、臨床試驗、分銷和最終用戶 - 2025-2030 年全球預測

Pharmacovigilance & Drug Safety Software Market by Product (Adverse Event Reporting Software, Drug Safety Audits Software, Fully Integrated Software), Clinical Trial (Phase I, Phase II, Phase III), Distribution, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年藥物安全檢測與藥物安全軟體市值為5.521億美元，預計2024年將達到6.2931億美元，到2030年將成長至14.2924億美元，複合年成長率為14.55%。

藥物安全檢測和藥物安全軟體透過確保對上市後藥物安全性的持續監測和評估，在醫療保健和製藥行業中發揮重要作用。對該軟體的需求源於不斷增加的藥物不良反應 (ADR) 發生率以及需要系統記錄和分析的嚴格政府法規。該軟體具有廣泛的應用範圍，包括藥物開發公司、CRO、製藥公司和監管機構，主要最終用戶是專注於患者安全和合規性的醫療保健專業人員和研究人員。市場成長是由人工智慧和機器學習等技術進步所推動的，這些技術進步增強了資料處理和預測分析能力。日益全球化和新藥發現的迅速增加進一步推動了需求。整合真實世界資料（RWD）以實現更準確的安全概況，以及開發雲端基礎的平台以改善各相關人員之間的可訪問性和協作，存在新的機會。然而，資料隱私問題、高實施成本和監管合規複雜性等挑戰可能會阻礙市場成長。此外，法規的地區差異需要靈活的軟體解決方案並增加了複雜性。這個產業的創新時機已經成熟，是增強訊號檢測技術和實施區塊鏈技術以確保資料完整性的完美領域。這些創新可以透過簡化業務和提高透明度來提供競爭優勢。由於大量不斷成長的供應商提供類似的解決方案，市場仍然競爭激烈且細分。因此，透過創新和客製化實現差異化是關鍵。公司應專注於使用者友善的介面和可擴展的解決方案，以服務小型到大型企業，並繼續推動監管指南的明確性，以簡化合規流程。透過專注於這些關鍵領域，公司可以有效克服藥物安全檢測和藥物安全軟體市場的挑戰並利用潛在機會。

主要市場統計
基準年[2023] 5.521 億美元
預測年份 [2024] 62931萬美元
預測年份 [2030] 1,429.24 百萬美元
複合年成長率（%） 14.55%

市場動態：揭示快速發展的藥物安全檢測和藥物安全軟體市場的關鍵市場洞察

供需的動態交互作用正在改變藥物安全檢測和藥物安全軟體市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 不良反應和藥物毒性發生率增加
    • 越來越需要減少審閱醫學文獻的時間
    • 高度監管的藥物安全檢測領域
  • 市場限制因素
    • 實施昂貴的藥物安全檢測和藥物安全軟體
  • 市場機會
    • 醫療公司增加研發（R&D）投資
    • 將人工智慧和機器學習模型整合到藥物安全檢測和藥物安全軟體中
  • 市場問題
    • 新興國家對藥物不良反應 (ADR) 缺乏認知、缺乏訓練和報告不足

波特五力：駕馭藥物安全檢測與藥物安全軟體市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解藥物安全檢測和藥物安全軟體市場的外部影響

外部宏觀環境因素在塑造藥物安全檢測和藥物安全軟體市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解藥物安全檢測和藥物安全軟體市場的競爭格局

藥物安全檢測和藥物安全軟體市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣：藥物安全檢測與藥物安全軟體市場供應商的績效評估

FPNV 定位矩陣是評估藥物安全檢測和藥物安全軟體市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

該報告提供了涵蓋關鍵焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 不良反應和藥物毒性發生率增加
      • 人們越來越需要減少審查醫學文獻以獲取總結報告和論文的時間。
      • 高度監管的藥品安全監測領域
    • 抑制因素
      • 藥物安全檢測和藥物安全軟體的部署成本高昂
    • 機會
      • 醫療公司增加研發（R&D）投資
      • 將人工智慧和機器學習模型整合到藥物安全檢測和藥物安全軟體中
    • 任務
      • 新興國家缺乏對藥物不良反應 (ADR) 的認知、培訓和報告
  • 市場區隔分析
    • 產品：增加藥品安全審核軟體的使用，確保遵守藥品安全監理法規
    • 最終用戶：藥物安全檢測和藥物安全軟體為合約研究機構處理臨床試驗資料並提供高級報告功能的潛力
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境
  • 客戶客製化

第6章藥物安全檢測與藥物安全軟體市場：依產品

  • 介紹
  • 不利事件通報軟體
  • 藥品安全審核軟體
  • 完全整合的軟體
  • 問題追蹤軟體

第7章藥物安全檢測與藥物安全軟體市場：透過臨床試驗

  • 介紹
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段
  • 臨床前

第8章藥物安全檢測與藥物安全軟體市場：依分佈

  • 介紹
  • 雲
  • 本地

第9章藥物安全檢測與藥物安全軟體市場：依最終使用者分類

  • 介紹
  • 業務流程外包公司
  • 合約研究組織
  • 製藥和生物技術公司
  • 藥品安全監測服務供應商

第10章美洲藥物安全檢測與藥物安全軟體市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太藥物安全檢測與藥物安全軟體市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲藥物安全檢測和藥物安全軟體市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • RxLogix 公司宣布與歐洲藥品管理局 (EMA) 建立突破性夥伴關係，提供尖端安全解決方案
    • JNPMEDI發布藥品安全管理解決方案“Maven Safety”

公司名單

  • Clinevo Technologies Private Limited
  • United BioSource LLC
  • Indegene Inc.
  • IQVIA Inc.
  • Accenture PLC
  • Freyr Software Services Pvt. Ltd.
  • Tepsivo Oy
  • ArisGlobal LLC
  • Clarivate
  • PureSoftware Limited
  • Anju Software, Inc.
  • TriNetX, LLC
  • Cognizant Technology Solutions Corporation
  • AB Cube SAS
  • Oracle Corporation
  • 4C Pharma Solutions
  • Wipro Limited
  • NUVO Consultancy
  • Infosys Limited
  • Cloudbyz, Inc.
  • Ennov SAS
  • Certara, Inc.
  • Sarjen Systems Private Limited
  • Sparta Systems, Inc.
  • Ergomed PLC
  • Extedo GmbH
Product Code: MRR-030EE4851600

The Pharmacovigilance & Drug Safety Software Market was valued at USD 552.10 million in 2023, expected to reach USD 629.31 million in 2024, and is projected to grow at a CAGR of 14.55%, to USD 1,429.24 million by 2030.

Pharmacovigilance and drug safety software plays a crucial role in the healthcare and pharmaceutical industries by ensuring the continual monitoring and assessment of drug safety, post-marketing. The necessity for this software arises from the increasing incidence of adverse drug reactions (ADRs) and stringent government regulations requiring systematic documentation and analysis. The application of this software spans drug development companies, CROs, pharmaceutical companies, and regulatory bodies, with the primary end-users being healthcare professionals and researchers focusing on patient safety and compliance. Market growth is driven by technological advancements such as AI and machine learning, which enhance data processing and predictive analytics capabilities. Increasing globalization and the surge in new drug discoveries further fuel the demand. Emerging opportunities exist in the integration of real-world data (RWD) for more accurate safety profiles and the development of cloud-based platforms to improve accessibility and collaboration across various stakeholders. However, challenges such as data privacy concerns, high implementation costs, and the complexity of regulatory compliance can hinder market growth. Furthermore, regional differences in regulations require flexible software solutions, adding layers of complexity. The industry is ripe for innovation, with the best areas being the enhancement of signal detection methodologies and the incorporation of blockchain technology to ensure data integrity. These innovations can provide competitive advantages by streamlining operations and enhancing transparency. While the market is growing, it remains competitive and fragmented, with numerous vendors offering similar solutions. Thus, differentiation through innovation and customization is key. Companies should focus on user-friendly interfaces and scalable solutions to cater to small and large enterprises alike, while continually lobbying for clearer regulatory guidelines to simplify compliance processes. By focusing on these critical areas, businesses can effectively navigate challenges and capitalize on the potential opportunities within the pharmacovigilance and drug safety software market.

KEY MARKET STATISTICS
Base Year [2023] USD 552.10 million
Estimated Year [2024] USD 629.31 million
Forecast Year [2030] USD 1,429.24 million
CAGR (%) 14.55%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmacovigilance & Drug Safety Software Market

The Pharmacovigilance & Drug Safety Software Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Incidence of ADR and Drug Toxicity
    • Increasing Need to Reduce Time Spent Reviewing Medical Literature for Aggregate Reports and Articles
    • Highly Regulated Pharmacovigilance Space
  • Market Restraints
    • Expensive Deployment of Pharmacovigilance & Drug Safety Software
  • Market Opportunities
    • Increasing Investment in Research and Development (R&D) by Healthcare Companies
    • Integration of AI and Machine Learning Models in Pharmacovigilance & Drug Safety Software
  • Market Challenges
    • Lack of Awareness, Training, and Underreporting of Adverse Drug Reactions (ADRs) in Developing Countries

Porter's Five Forces: A Strategic Tool for Navigating the Pharmacovigilance & Drug Safety Software Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmacovigilance & Drug Safety Software Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmacovigilance & Drug Safety Software Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmacovigilance & Drug Safety Software Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmacovigilance & Drug Safety Software Market

A detailed market share analysis in the Pharmacovigilance & Drug Safety Software Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmacovigilance & Drug Safety Software Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmacovigilance & Drug Safety Software Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pharmacovigilance & Drug Safety Software Market, highlighting leading vendors and their innovative profiles. These include Clinevo Technologies Private Limited, United BioSource LLC, Indegene Inc., IQVIA Inc., Accenture PLC, Freyr Software Services Pvt. Ltd., Tepsivo Oy, ArisGlobal LLC, Clarivate, PureSoftware Limited, Anju Software, Inc., TriNetX, LLC, Cognizant Technology Solutions Corporation, AB Cube S.A.S., Oracle Corporation, 4C Pharma Solutions, Wipro Limited, NUVO Consultancy, Infosys Limited, Cloudbyz, Inc., Ennov SAS, Certara, Inc., Sarjen Systems Private Limited, Sparta Systems, Inc., Ergomed PLC, and Extedo GmbH.

Market Segmentation & Coverage

This research report categorizes the Pharmacovigilance & Drug Safety Software Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Adverse Event Reporting Software, Drug Safety Audits Software, Fully Integrated Software, and Issue Tracking Software.
  • Based on Clinical Trial, market is studied across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical.
  • Based on Distribution, market is studied across On-Cloud and On-Premise.
  • Based on End User, market is studied across Business Process Outsourcing Firms, Contract Research Organizations, Pharma & Biotech Companies, and Pharmacovigilance Service Providers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Incidence of ADR and Drug Toxicity
      • 5.1.1.2. Increasing Need to Reduce Time Spent Reviewing Medical Literature for Aggregate Reports and Articles
      • 5.1.1.3. Highly Regulated Pharmacovigilance Space
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive Deployment of Pharmacovigilance & Drug Safety Software
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing Investment in Research and Development (R&D) by Healthcare Companies
      • 5.1.3.2. Integration of AI and Machine Learning Models in Pharmacovigilance & Drug Safety Software
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of Awareness, Training, and Underreporting of Adverse Drug Reactions (ADRs) in Developing Countries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing usage of drug safety audit software to ensure compliance with pharmacovigilance regulations
    • 5.2.2. End User: Potential of pharmacovigilance & drug safety software among contract research organizations for handling clinical trial data and offering advanced reporting capabilities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Pharmacovigilance & Drug Safety Software Market, by Product

  • 6.1. Introduction
  • 6.2. Adverse Event Reporting Software
  • 6.3. Drug Safety Audits Software
  • 6.4. Fully Integrated Software
  • 6.5. Issue Tracking Software

7. Pharmacovigilance & Drug Safety Software Market, by Clinical Trial

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV
  • 7.6. Pre-clinical

8. Pharmacovigilance & Drug Safety Software Market, by Distribution

  • 8.1. Introduction
  • 8.2. On-Cloud
  • 8.3. On-Premise

9. Pharmacovigilance & Drug Safety Software Market, by End User

  • 9.1. Introduction
  • 9.2. Business Process Outsourcing Firms
  • 9.3. Contract Research Organizations
  • 9.4. Pharma & Biotech Companies
  • 9.5. Pharmacovigilance Service Providers

10. Americas Pharmacovigilance & Drug Safety Software Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pharmacovigilance & Drug Safety Software Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pharmacovigilance & Drug Safety Software Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. RxLogix Corporation Announces Landmark Partnership with the European Medicines Agency (EMA) for a Cutting-Edge Safety Solution
    • 13.3.2. Launch by JNPMEDI of 'Maven Safety,' a drug safety management solution

Companies Mentioned

  • 1. Clinevo Technologies Private Limited
  • 2. United BioSource LLC
  • 3. Indegene Inc.
  • 4. IQVIA Inc.
  • 5. Accenture PLC
  • 6. Freyr Software Services Pvt. Ltd.
  • 7. Tepsivo Oy
  • 8. ArisGlobal LLC
  • 9. Clarivate
  • 10. PureSoftware Limited
  • 11. Anju Software, Inc.
  • 12. TriNetX, LLC
  • 13. Cognizant Technology Solutions Corporation
  • 14. AB Cube S.A.S.
  • 15. Oracle Corporation
  • 16. 4C Pharma Solutions
  • 17. Wipro Limited
  • 18. NUVO Consultancy
  • 19. Infosys Limited
  • 20. Cloudbyz, Inc.
  • 21. Ennov SAS
  • 22. Certara, Inc.
  • 23. Sarjen Systems Private Limited
  • 24. Sparta Systems, Inc.
  • 25. Ergomed PLC
  • 26. Extedo GmbH

LIST OF FIGURES

  • FIGURE 1. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ADVERSE EVENT REPORTING SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DRUG SAFETY AUDITS SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY FULLY INTEGRATED SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ISSUE TRACKING SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ON-CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY BUSINESS PROCESS OUTSOURCING FIRMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHARMACOVIGILANCE SERVICE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET, FPNV POSITIONING MATRIX, 2023